skip to main
|
skip to sidebar
KinasePro
Daily news on kinase inhibitors.
Saturday, August 23, 2008
Selectivity Prediction - Pfizer
Predicting Kinase Selectivity Profiles Using Free-Wilson QSAR Analysis.
Sciabola S, Stanton RV, Wittkopp S, Wildman S, Moshinsky D, Potluri S, Xi H.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Labels
550
(1)
Abbott
(1)
Akt
(1)
Amgen
(1)
Angiokinase
(1)
Astellas
(1)
Aurora2
(1)
Axitinib
(1)
B-Raf
(2)
BMS
(2)
Boehringer Ingelheim
(1)
C-MET
(2)
CAMK2A
(1)
CDK
(1)
CEP-1347
(1)
Cephalon
(2)
CK1e
(1)
Clinical Trial
(10)
Computational
(4)
CP-690
(1)
Dasatinib
(1)
Eberhard-Karls-University Tuebingen
(1)
EGFR
(1)
Genentech
(1)
GSK
(2)
GSK3
(1)
IGF-1R
(1)
IRAK4
(1)
JAK2
(1)
JNK
(1)
Lapatinib
(1)
Lck
(1)
Motesanib
(1)
mTOR
(1)
Nilotinib
(1)
p38
(2)
PDB
(3)
PDK1
(1)
Pfizer
(3)
Phase II
(1)
PI3K
(2)
Pim1
(1)
Piramed
(1)
PKA
(1)
PLK
(1)
Plk1
(1)
Riboxistaurin
(1)
Sorafenib
(1)
Src
(1)
Sunitinib
(1)
Tie1
(1)
TrkA
(1)
UCB
(1)
University of Florida
(1)
University of Kentucky
(1)
University of Pittsburgh
(1)
University of Rhode Island
(1)
Blog Archive
►
2009
(1)
►
07/05 - 07/12
(1)
▼
2008
(32)
►
09/07 - 09/14
(3)
►
08/31 - 09/07
(10)
►
08/24 - 08/31
(11)
▼
08/17 - 08/24
(8)
B-Raf - Furans- GSK
PDK1 Modeling - University of Kentucky
Selectivity Prediction - Pfizer
Patent Applications - 08/22/2008
PDB Update 08/21/08
Review of Computational Methods - Cephalon
Lck - University of Pittsburgh
Angiokinase - Boehringer Ingelheim
On the Market
Dasatinib
Erlotinib
Gefitinib
Imatinib
Lapatinib
Nilotinib
Temsirolimus
No comments:
Post a Comment